Travere Says FDA Has Granted Full Approval To FILSPARI (Sparsentan) To Slow Kidney Function Decline In Adults With Primary IgAN Who Are At Risk Of Disease Progression
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics announced that the FDA has granted full approval to FILSPARI (Sparsentan) for slowing kidney function decline in adults with primary IgAN. This follows positive results from the PROTECT Study, which showed significant benefits over two years compared to irbesartan.
September 05, 2024 | 9:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics received full FDA approval for FILSPARI, which is expected to positively impact the company's stock due to the drug's proven efficacy in slowing kidney function decline in IgAN patients.
The full FDA approval of FILSPARI is a major milestone for Travere Therapeutics, as it validates the drug's efficacy and safety profile. This approval is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100